BioSpace News Archive

Aphena Pharma Solutions Inc. announced that it has approved $7 million for company-wide expansion for future growth opportunities to be completed by the end of 2019.

Advaxis, Inc. announced that the U.S. Food and Drug Administration has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac for the treatment of patients with high-risk locally advanced cervical cancer.

Sobi announced the publication of data demonstrating the impact of hospitalizations due to respiratory syncytial virus on caregivers of high-risk preterm infants in the U.S. The study, which was published in the journal Clinical Pediatrics, showed that these caregivers experienced missed work, diminished work productivity, emotional stress, disruption of family routine and financial concerns, many of which persisted at least one month following hospital discharge.

Seattle Genetics, Inc. announced that management will present at the RBC Capital Markets 2019 Global Healthcare Conference on Wednesday, May 22, 2019 at 8:30 a.m. Eastern Time.

Alliance will Utilize Technology from Applied DNA Sciences in ETCH biotrace™ to Secure Supply Chains

Elligo Health Research announces the launch of its innovative IntElligo Research Stack™ clinical technology.

Brett Lansing will help lead IT strategy and operations for the company’s transformative digital health, care management and population health solutions

NeuClone Pharmaceuticals Ltd. announced it will initiate the Phase I clinical trial of its Stelara® biosimilar in the second half of 2019.

Asteres Inc. announced that it has named Valerie Gionis Vice President of Marketing and Customer Experience.

Acucela Inc. announced that it has appointed Robert “Bob” J. Stevens to its Board of Directors.